Axogen, Inc. develops and commercializes surgical solutions for peripheral nerve regeneration and repair. The company’s recurring updates center on its portfolio for restoration of peripheral nerve function, including Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
Company news also includes quarterly and annual financial results, revenue guidance, gross margin and cash metrics, investor-conference participation, FDA-related developments for Avance, and capital-structure actions involving common stock. These updates connect operating performance with Axogen’s commercial activity in nerve repair products across its target markets.
Axogen, Inc. (NASDAQ: AXGN) reported Q1 2020 net revenue of $24.3 million, a 4% increase from Q1 2019. However, gross margin declined to 80.1%. The company posted a net loss of $8.2 million or $0.21 per share, compared to a loss of $9.5 million in the same quarter last year. Active accounts rose by 13% to 825. Due to COVID-19, the company suspended its 2020 guidance, foreseeing reduced revenues. Additionally, Axogen returned a $7.8 million PPP loan amid changing eligibility standards. A class action lawsuit was dismissed, and cost-cutting measures were implemented.